Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PA5S
|
|||
| Former ID |
DAP000658
|
|||
| Drug Name |
Risedronate
|
|||
| Synonyms |
Risedronic acid; 105462-24-6; Actonel; Atelvia; Acido risedronico; Acidum risedronicum; Benet; Risedronic acid [INN:BAN]; Acidum risedronicum [INN-Latin]; Acido risedronico [INN-Spanish]; Acide risedronique [INN-French]; Risedronic acid monohydrate; NE-58095; UNII-KM2Z91756Z; C7H11NO7P2; NE 58019; HSDB 7326; [1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid; Risedronic acid (Actonel); CHEMBL923; CHEBI:8869; Phosphonic acid,; Benet; RIS; Ridron; Acide risedronique; Bisphosphonate 1; Actonel (TN); Ridron (TN); Risedronic acid (INN); (1-Hydroxy-2-(3-pyridyl)ethylidene)diphosphonic acid; (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid; (1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid); 1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE BIS-PHOSPHONIC ACID
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Paget's disease [ICD-11: FB85; ICD-9: 731] | Approved | [1], [2] | |
| Therapeutic Class |
Bone Density Conservation Agents
|
|||
| Company |
Procter & Gamble; Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H11NO7P2
|
|||
| Canonical SMILES |
C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
|
|||
| InChI |
1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
|
|||
| InChIKey |
IIDJRNMFWXDHID-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 105462-24-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10432, 634947, 854702, 854710, 5611888, 7890278, 7980522, 8024683, 8153227, 14799749, 26717653, 29224300, 46506784, 46507526, 46513033, 48416522, 50064108, 50489232, 53790968, 56479319, 57322678, 81040440, 81063165, 92309057, 92712985, 93166168, 96025170, 103240839, 104308679, 125337191, 126625112, 126656394, 126670227, 128171553, 131293655, 134337947, 134340432, 135018951, 135650902, 135692314, 136990826, 137003756, 142093192, 143493311, 144080110, 152031983, 152242566, 160964225, 162178465, 164205287
|
|||
| ChEBI ID |
CHEBI:8869
|
|||
| ADReCS Drug ID | BADD_D01949 ; BADD_D01950 | |||
| SuperDrug ATC ID |
M05BA07
|
|||
| SuperDrug CAS ID |
cas=105462246
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Geranyltranstransferase (FDPS) | Target Info | Inhibitor | [3], [4] |
| BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | |||
| Superpathway of cholesterol biosynthesis | ||||
| Trans, trans-farnesyl diphosphate biosynthesis | ||||
| Geranylgeranyldiphosphate biosynthesis | ||||
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Influenza A | ||||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Cholesterol biosynthesis | |||
| Pathwhiz Pathway | Steroid Biosynthesis | |||
| Reactome | Cholesterol biosynthesis | |||
| Activation of gene expression by SREBF (SREBP) | ||||
| WikiPathways | Activation of Gene Expression by SREBP (SREBF) | |||
| SREBP signalling | ||||
| Cholesterol Biosynthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3176). | |||
| REF 2 | Risedronate for treatment of osteoporosis. Nippon Rinsho. 2009 May;67(5):948-53. | |||
| REF 3 | Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14. | |||
| REF 4 | In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother. 2002 Mar;46(3):929-31. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.